{"entity":{"id":"nct03379428","kind":"trial","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Trastuzumab and Ibrutinib in advanced solid tumours, run by US Oncology Research, active and no longer recruiting.","summary":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT03379428 by US Oncology Research, with 34 participants enrolled, started 2017-11-29 and due to reach its primary completion in 2025-01. Interventions recorded: Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg and Ibrutinib 420 mg.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03379428","url":"https://clinicaltrials.gov/study/NCT03379428"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","ibrutinib"],"companies":["mckesson-us-oncology","abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03379428","phase":"1/2","setting":"Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","sponsor":"US Oncology Research","enrolled":34,"outcomes":[]},"route":"/trials/nct03379428/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/"}]}}